Welcome to BioSeeker Group!

Triple Analysis: Lung Cancer, Apoptosis and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3953
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Lung Cancer, Apoptosis and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Apoptosis and Peptides.

    To find out more about Triple Analysis: Lung Cancer, Apoptosis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Apoptosis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer
The lung cancer report part comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 218 investigators, from Ceased to Marketed. This part extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and and three subindications of lung cancer.
This part is based on the following publication:
Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Lung Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Lung Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (241 Drug Targets) 35-526
7 Emerging New Products to Established Ones: Drug Target Strategies of Lung Cancer Drugs by their Highest Stage of Development (237 Drug Target Strategies and 416 Lung Cancer Drugs) 527-817
8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Drugs by Compound Strategy (8 Compound Strategies) 818-870
9 Selecting Subindication for Lung Cancer Drugs (Three Subindications of Lung Cancer) 871-898
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lung Cancer Drug Pipeline by Investigator (218 Companies) 899-1299
11 Disclaimer 1300
12 Drug Index 1301
13 Company Index 1314
Figures: Includes 7 Figures
Tables: Includes 284 Tables
Total Number of Pages: 1323

Part II: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
A&G Pharmaceutical
Abbott
Acceleron Pharma
Access
Active Biotech
Adherex
Advanced Life Sciences
Advanomics
Advantagene
AEgera
AEterna Zentaris
Affymax
Agennix
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Allos Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Altor BioScience
Ambrilia Biopharma
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
AplaGen Biopharmaceuticals
Apogenix
ApopLogic Pharmaceuticals
Apotex
Ardana
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
Avila Therapeutics
Axelar
Basilea Pharmaceutica
Baxter International
Bayer
Benitec
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
BioInvent
Biokine Therapeutics
BioLineRx
Biomas
Bionovo
BioNumerik
BioSante
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
Chiasma
Chlorogen
Chong Kun Dang
Chroma Therapeutics
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Clinuvel
CLL Pharma
CombinatoRx
Compugen
Coronado Biosciences
Critical Outcome Technologies
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Dendreon
DeveloGen
Digna Biotech
Dong-A
Dongkook Pharm
ECI
Eisai
Elara Pharmaceuticals
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Enkam Pharmaceuticals
EntreMed
EpiCept
Erimos
Esperance Pharmaceuticals
Exelixis
Formula Pharmaceuticals
Fresenius
Galapagos
Galena Biopharma
Gemin X Biotechnologies
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlobeImmune
GlycoGenesys
Glycotope
GP Pharm
GPC Biotech
Gradalis
Green Cross
Gryphon Therapeutics
Hanmi
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intezyne Technologies
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kalypsys
Karyon-CTT
Keryx Biopharmaceuticals
Kiadis
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Ligand
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mirna Therapeutics
MolMed
Mologen
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurobiological Technologies
Neurocrine Biosciences
NewSouth Innovations
Nidus Laboratories
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novelix
Novogen
NPS Pharmaceuticals
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Orchestra Therapeutics
OSI Pharmaceuticals
OXiGENE
Paladin Labs
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
Pierre Fabre
Pro-Pharmaceuticals
Progen Pharmaceuticals
ProMetic Life Sciences
Protagonist
Q Chip
QLT
Raptor Pharmaceutical
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Rosetta Genomics
Samyang
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Serometrix
ShimodaAtlantic Oncology
Shire
Sigma-Tau
Silence Therapeutics
Simcere Pharmaceuticals
Sirnaomics
Soligenix
Spectrum Pharmaceuticals
SRI International
SuperGen
Supratek Pharma
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
SynDevRx
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Taxolog
Tekmira Pharmaceuticals
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Titan Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
TriAct Therapeutics
Trion Pharma
UCB
UMN Pharma
Unigene
United Biomedical
Valeant
ValiRx
Vaxil BioTherapeutics
Vaxon Biotech
VaxOnco
VBL Therapeutics
Velacor Therapeutics
Vernalis
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
Viragen
Viralytics
ViroTarg
VM Discovery
Wyeth
Xerion
Xigen
Xoma
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zensun
Zhejiang Beta Pharma
Zivena
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abarelix
ABT-510
AEG-35156
AEZS-108
afamelanotide
afatinib
aflibercept
alvocidib
AME-133
amrubicin hydrochloride
angiopep+paclitaxel
APG-101
ARQ-197
AS-101
AS-1411
astuprotimut-r
bardoxolone methyl
belagenpumatucel-L
belinostat
belotecan hydrochloride
bevacizumab
BIBF-1120
bortezomib
bosutinib
BZL-101
canfosfamide hydrochloride
CBP-501
celecoxib
cenersen
cetuximab
cintredekin besudotox
conatumumab
corticorelin acetate
crizotinib
crolibulin
dacomitinib
deslorelin
dinaciclib
docetaxel
dulanermin
E-75
emepepimut-S
endostatin
enzastaurin hydrochloride
EP-100
erlotinib
etoposide (1)
etoposide phosphate
fosbretabulin tromethamine
FPI-01
gataparsen
gefitinib
goserelin
GT-111
GV-1001
GX-301
HE-3235
Her-2/Neu peptides
histrelin
ibritumomab tiuxetan
icotinib hydrochloride
idronoxil
imatinib mesilate
imetelstat
imMucin
iniparib
interferon (gamma1b)
IPP-204106
irinotecan hydrochloride
ISA-P53-01
kahalalide F
lanreotide
lapatinib ditosylate
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
litronesib
lonaprisan
lumiliximab
mapatumumab
MDX-1379
MKC-1
mocetinostat
motesanib diphosphate
motexafin gadolinium
nadroparin
NAFB001
navitoclax
necitumumab
netupitant
nimotuzumab
noscapine
obinutuzumab
oblimersen sodium
octreotide
octreotide, LAR
ON-01910
Oncohist
OTS-102
ozarelix
paclitaxel
paclitaxel polyglumex
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
pazopanib hydrochloride
PBI-1402
PCI-24781
pemetrexed disodium
plitidepsin
polyclonal antibody stimulator
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
retaspimycin
rindopepimut
romurtide
sagopilone
seliciclib
sorafenib tosylate
sotatercept
SPC-2996
ß-lapachone
SU-6668
Survivac
talactoferrin alfa
tegafur + uracil
terameprocol
thymalfasin
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
TM-30339
topotecan
triciribine phosphate
TRU-016
TS-1
vapreotide, immediate-release
vitespen
volasertib
vosaroxin
VX-001
XL-147
XL-647

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Lung Cancer, Apoptosis and Peptides.
    To find out more about Triple Analysis: Lung Cancer, Apoptosis and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Lung Cancer, Apoptosis and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Leukemia and Peptides
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Leukemia and by the compound strategy of Peptides. Learn More


Triple Analysis: Leukemia, Apoptosis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines. Learn More

Other selected research from the 'Oncology' category:


Protein Kinase Inhibitors in Oncology Drug Pipeline Update
BioSeeker Group have identified 462 companies plus partners who are today developing 831 PKI drugs in 2912 developmental projects in cancer across 296 different targets. In addition, there are 5 suspended drugs and another 459 drugs where development has been ceased. Learn More


Cancer Immunotherapy: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of immuno-oncology. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More